Beijing, China: Adcendo exercises its option to utilize Biocytogen’s fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need This collaboration further validates Biocytogen’s proprietary RenMice® antibody discovery platform, demonstrating its potential to advance innovative therapies for patients Biocytogen Pharmaceuticals …
